Gregory Covino - Biogen Idec Insider

$293.21  0.91  0.31%

Chief Accounting Officer, VP of Fin. and Controller

Mr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Idec Inc. since April 2012. Prior to that Mr. Covino served at Boston Scientific Corporationrationration a medical device company as Vice President Corporationrationrate Analysis and Control since March 2010 having responsibility for the company internal audit function and as Vice President Finance International from February 2008 to March 2010 having responsibility for the financial activities of the company international division. Prior to that Mr. Covino held several finance positions at Hubbell Incorporated an electrical products company including Vice President Chief Accounting Officer and Controller from 2002 to January 2008 Interim Chief Financial Officer from 2004 to 2005 and Director Corporationrationrate Accounting from 1999 to 2002
Age: 48  VP Since 2012      

Other Appointments

Gregory Covino Education
Covino received his B.S. in Business Administration from Bryant University.

Management Efficency

The company has return on total asset (ROA) of 17.76 % which means that it generated profit of $17.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 34.74 % meaning that it created $34.74 on every $100 dollars invested by stockholders.
The company currently holds 6.53 B in liabilities with Debt to Equity (D/E) ratio of 0.62 which is about average as compared to similar companies. Biogen Idec Inc has Current Ratio of 3.45 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Filter Other Executives

Click to run this filter
Filter Other Insiders

Found 2 records

VP Since

Patrick IIICelgene Corporation
Michael BoothIncyte Corporation

Entity Summary

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 7,550 people.
NameBiogen Idec Inc
InstrumentUSA Stock
Analyst ConsensusBuy 21 Opinions
Risk-adjusted AdviceStrong Hold Under Valued
Average Bond RatingBBB Adequate
CurrencyUSD - US Dollar
DescriptionBiogen Inc. discovers develops manufactures and markets therapies for the treatment of neurological autoimmune and hematologic disorders in the United States and internationally. more
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Idec Inc to your portfolio

Biogen Idec Leadership

Lynn Schenk, Director
Adriana Karaboutis, EVP
Steven Holtzman, President
Paul Clancy, CFO, MBA
John Cox, EVP, MBA
Gregory Covino, VP
Robert Pangia, Director
Eric Rowinsky, Director, Ph.D
Caroline Dorsa, Director
Douglas Williams, EVP
Stuart Kingsley, EVP
Richard Mulligan, Director
Stelios Papadopoulos, Chairman, Ph.D
George Scangos, CEO, Ph.D
Alexander Denner, Director
Brian Posner, Director
Stephen Sherwin, Director, Ph.D
Susan Alexander, President
Adriana MS, EVP
MD, Sandrock, SVP
Kenneth Pietro, President
Tony Kingsley, President, MBA
Matt Griffiths, President
Nancy Leaming, Director
Alfred Sandrock, President, Ph.D
Spyros Artavanis-Tsakonas, President, Ph.D
Adam Koppel, President, MBA

Stock Performance